In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
about
Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver InjuryRole of endoplasmic reticulum stress in drug-induced toxicityMechanisms of drug-induced liver injuryRho-kinase/myosin light chain kinase pathway plays a key role in the impairment of bile canaliculi dynamics induced by cholestatic drugs.Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in manKey Challenges and Opportunities Associated with the Use of In Vitro Models to Detect Human DILI: Integrated Risk Assessment and Mitigation PlansDrug-induced liver injury: recent advances in diagnosis and risk assessment.How Open Data Shapes In Silico Transporter Modeling.Hepatocellular exposure of troglitazone metabolites in rat sandwich-cultured hepatocytes lacking Bcrp and Mrp2: interplay between formation and excretion.Mechanistic Modeling Reveals the Critical Knowledge Gaps in Bile Acid-Mediated DILITimosaponin A3 induces hepatotoxicity in rats through inducing oxidative stress and down-regulating bile acid transporters.Sandwich-cultured hepatocytes: utility for in vitro exploration of hepatobiliary drug disposition and drug-induced hepatotoxicity.Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury.An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters.Toward predicting drug-induced liver injury: parallel computational approaches to identify multidrug resistance protein 4 and bile salt export pump inhibitors.Species differences in hepatobiliary disposition of taurocholic acid in human and rat sandwich-cultured hepatocytes: implications for drug-induced liver injuryThe physiological role of drug transporters.Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicityCombination lopinavir and ritonavir alter exogenous and endogenous bile acid disposition in sandwich-cultured rat hepatocytes.Inhibition of hepatic cytochrome P450 enzymes and sodium/bile acid cotransporter exacerbates leflunomide-induced hepatotoxicitySandwich-Cultured Hepatocytes as a Tool to Study Drug Disposition and Drug-Induced Liver Injury.Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.Biosynthesis and trafficking of the bile salt export pump, BSEP: therapeutic implications of BSEP mutations.Assessment of gadoxetate DCE-MRI as a biomarker of hepatobiliary transporter inhibitionHepatic 3D spheroid models for the detection and study of compounds with cholestatic liability.Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11).Functional human induced hepatocytes (hiHeps) with bile acid synthesis and transport capacities: A novel in vitro cholestatic model.Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver.Idiosyncratic Drug-Induced Liver Injury (IDILI): Potential Mechanisms and Predictive Assays.The role of bile salt export pump gene repression in drug-induced cholestatic liver toxicity.Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4.The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury.The right compound in the right assay at the right time: an integrated discovery DMPK strategy.Emerging transporters of clinical importance: an update from the International Transporter Consortium.In vitro methods to support transporter evaluation in drug discovery and development.Linking physiology to toxicity using DILIsym®, a mechanistic mathematical model of drug-induced liver injury.High-content analysis/screening for predictive toxicology: application to hepatotoxicity and genotoxicity.Hepatobiliary transporters in drug-induced cholestasis: a perspective on the current identifying tools.Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics.Autoimmune BSEP disease: disease recurrence after liver transplantation for progressive familial intrahepatic cholestasis.
P2860
Q26749054-CC57490E-AD3A-4395-880E-E533D37801CFQ26765518-CA22C8EF-5A28-4533-A9FD-04CB0974BABCQ26998806-288812CB-9051-4315-87A9-95618AA5D877Q27320565-4CAAEAAB-A6C4-4992-93A9-932FE2FD43F6Q28069617-8F3238AB-56E7-42FB-8EA6-5FCB338AE62CQ28075991-5D8B0B3B-ADCB-43E7-867E-69589DB0F65EQ30235089-81ACF222-531C-4848-A1EC-63309430F8F3Q30491084-DA24B869-551B-42C9-BB5E-2B3B8C49DC50Q33742713-72DF67EA-BB61-4D7F-A6F8-1C955DEBB171Q33994553-B619F26E-2A60-4A27-ACDE-E8408046DDECQ34138386-D37294A9-06A9-4DD7-ABA7-725C0AECB281Q34330504-75CD57CA-2C86-4028-9C96-AD2003B00074Q34471194-94D217CC-1FDA-4785-AA6F-3031874F1369Q35206374-BC8760EE-938B-4677-8A39-B7C7C2BD3130Q35531766-7E9D269B-251D-4BA5-9383-E3DA729EF250Q35531814-DC7FF825-E59B-459C-BA53-51A1144C7447Q35563701-90FB2EAC-488A-4C1E-A733-6CFA69E17DD2Q35781894-4170BBF1-D1BE-4C48-BEE1-ED7FB6390FACQ36497674-85B7C4AD-DEA5-493B-888D-E53C1305D939Q36644296-66483A7F-9EB9-4B73-A86B-0E7099380C80Q36972804-1115BC87-2256-4050-9B3A-AF55D6389ADDQ37121662-A3ADA232-7D2B-498E-9C42-D5E2808359D9Q37200971-EC47EB6E-3636-4600-A9FB-B3DD28DDB708Q37279800-25D98F1F-CDB2-4224-B9FC-EB6B92F1040CQ37349147-FABCDE90-3073-4BEA-8DED-706CE8057FD1Q37380777-E7537630-31C4-45DD-9FC2-CFFFF532FB01Q37487339-5DAB61B0-1B63-4597-B364-6DF620AEFC89Q37504548-6410D8BB-BED7-4D4E-BC4B-5AB0D5C64E6EQ37590883-66B03809-A2C0-4213-8B8B-6C064D9A7501Q37603877-8233ED0C-0111-4227-AC82-44CDA5453862Q37663395-50558934-EE65-43F1-92BB-BD1A97F9A503Q37979858-49177573-D5F5-4461-B03F-EA05BA81597BQ38018653-E43326E3-13A7-427A-8FAA-7350F1419859Q38099192-DB57A66A-0E26-4167-BCAC-469335C2D604Q38099194-E27A151C-3232-4C26-B91B-7D0EA90E54B4Q38161471-4FD4FAE6-3005-46D6-8BC6-E61FA8BC4A8AQ38181625-9721E315-620C-4C3F-8A90-86AEC009C311Q38192698-EE1182EC-7BA3-4B4D-A6E0-03A0AF93EDA0Q38207943-D7DAD9C0-FA61-45C6-B6E8-C483774BAF00Q38262461-837EFE01-9B96-48AD-A574-27DA5CA7E8DB
P2860
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
In vitro inhibition of the bil ...... nduced liver injury in humans.
@en
In vitro inhibition of the bil ...... nduced liver injury in humans.
@nl
type
label
In vitro inhibition of the bil ...... nduced liver injury in humans.
@en
In vitro inhibition of the bil ...... nduced liver injury in humans.
@nl
prefLabel
In vitro inhibition of the bil ...... nduced liver injury in humans.
@en
In vitro inhibition of the bil ...... nduced liver injury in humans.
@nl
P50
P356
P1476
In vitro inhibition of the bil ...... induced liver injury in humans
@en
P2093
Jane Barber
Sarah Dawson
P304
P356
10.1124/DMD.111.040758
P577
2011-09-30T00:00:00Z